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Abstract
Background: The control of growth and nutritional status in the foetus and neonate is a complex mechanism, in
which also hormones produced by adipose tissue, such as adiponectin and leptin are involved. The aim of this
study was to evaluate levels of adiponectin, leptin and insulin in appropriate (AGA) and small for gestational age
(SGA) children during the 1
st year of life and to correlate these with auxological parameters.
Methods: In 33 AGA and 29 SGA infants, weight, length, head circumference, glucose, insulin, adiponectin and
leptin levels were evaluated at the second day of life, and at one, six and twelve months, during which a portion
of SGA could show catch-up growth (rapid growth in infants born small for their gestational age).
Results: Both total and isoform adiponectin levels were comparable between AGA and SGA infants at birth and
until age one year. These levels significantly increased from birth to the first month of life and then decreased to
lower values at 1 year of age in all subjects. Circulating leptin concentrations were higher in AGA (2.1 ± 4.1 ng/ml)
than in SGA neonates (0.88 ± 1.03 ng/ml, p < 0.05) at birth, then similar at the 1
st and the 6
th month of age, but
they increased in SGA from six months to one year, when they showed catch-up growth. Circulating insulin levels
were not statistically different in AGA and SGA neonates at any study time point. Insulin levels in both AGA and
SGA infants increased over the study period, and were significantly lower at birth compared to one, six and 12
months of age.
Conclusions: During the first year of life, in both AGA and SGA infants a progressive decrease in adiponectin levels
was observed, while a difference in leptin values was correlated with the nutritional status.
Background
Epidemiological studies have shown an association
between a reduced size at birth and increased long-term
risk for obesity, insulin resistance, type 2 diabetes, hyper-
tension and cardiovascular disease in adulthood [1-3].
Low birth weight has been associated with hyperinsuli-
naemia in both children [4,5] and adults [6], suggesting
that this metabolic abnormality may be the link between
reduced prenatal growth and certain endocrinological dis-
eases in adulthood. In particular, the transition from a
relatively low birth weight to larger post-natal body size
is associated with an increased risk for insulin resistance
[7-9]. It, therefore, seems that small birth size, and parti-
cularly low birth weight are factors that greatly increase
the risk of developing endocrine and metabolic diseases
in adulthood [9].
A role for adipose tissue in the pathophysiology of
insulin resistance has been postulated in several studies
[10]. It is currently known to secrete a large number of
factors with diverse functions, such as free fatty acids,
with well described physiological and pathophysiological
effects on glucose homeostasis [11], and proteins,
termed adipocytokines, that act in an autocrine, para-
crine, or endocrine fashion to control various metabolic
functions. Some of these adipocytokines, such as adipo-
nectin, leptin, tumour necrosis factor-a (TNF-a)a n d
interleukin-6 (IL-6), may act locally or distally to alter
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muscle and the liver or may act through neuroendo-
crine, autonomic or immune pathways [12]. Adiponectin
and leptin are considered the most important hormones
related to adipose depots in modulating metabolism and
energy homeostasis [12].
In adult humans, plasma adiponectin is an important
insulin sensitizer, as its circulating level is inversely
related to the body mass index and to measures of insu-
lin resistance [13]. Since foetal growth is to a great
extent controlled by the actions of insulin, adiponectin
could also be expected to have significant effects on foe-
tal growth and development. In the circulation, adipo-
nectin exists as low-, medium- and high molecular
weight complexes that appear to elicit different effects
on target tissues [14]. In particular, the high molecular
weight isoform has been linked with insulin-sensitizing
activity [15].
Circulating leptin concentrations, mainly produced by
white adipose tissue, correlate with the development of
foetal adipose tissue and later with the body mass index
[16]. The role of leptin among the complex network of
factors controlling foetal growth is incompletely under-
stood, even though recent studies have demonstrated a
strong correlation between leptin in cord blood and foe-
tal birth weight [17,18].
T h ea i mo ft h ep r e s e n ts t u d yw a st oe v a l u a t es e r u m
levels of leptin, adiponectin and insulin in infants born
appropriate for gestational age (AGA) and small for
gestational age (SGA) during the first year of life and to
correlate these changes with auxological parameters.
Methods
Thirty-three AGA (birth weight > -2 SD according to
gestational age and gender) [19] infants (21 males and
12 females) and 29 SGA (birth weight < -2 SD accord-
ing to gestational age and gender) infants (19 males and
10 females), participated in the study. According to
gestational age at delivery, all the neonates were full-
term (38 ± 1 weeks of gestation). Gestational age at
delivery was calculated according to the last menstrual
period and confirmed by ultrasound examination during
the first trimester or early second trimester. The
mothers of the neonates enrolled confirmed the normal
course of the pregnancy, without any complications or
administration of drugs. Thirty-five neonates (17 SGA
and 18 AGA) were born by eutocic birth, while 27 (12
SGA and 15 AGA) were delivered by caesarean section.
Neonates were randomly recruited at birth from the
Neonatal Units of the Spedali Civili Hospital of Brescia
and the San Matteo Hospital of Pavia, Italy.
Subjects with evidence of malformations or genetic
disorders were excluded from the study. Mid-parental
height, used as an indicator of the genetic growth
potential, was similar in AGA (mean ± standard devia-
tion: 0.31 ± 0.82 SDS, standard deviation score) and
SGA groups (-0.12 ± 0.85 SDS).
Among SGA infants, 16 were symmetrical and 13
asymmetrical. We defined “symmetrical SGA” neonates
as having both birth length and weight less than 2 SDS
corrected for gestational age and “asymmetrical SGA”
neonates with birth weight only less than -2 SDS cor-
rected for gestational age.
The infants had similar diets, during the first year of
life, they received only milk until the fourth month,
then one solid meal was introduced at the sixth month
and two solid meals at the eighth month.
In all infants, weight, length and head circumference
were evaluated at the second day of life, and at one, six
and 12 months by a trained paediatrician, and converted
to SDS to adjust for age and sex [20,21]. The body mass
index (BMI) was used as a measurement of relative
adiposity and was calculated according to the formula:
weight (Kg)/length
2 (m
2) [21].
At regularly scheduled control visit, a blood sample
was obtained from each neonate (in the fasting state)
for the determination of glucose, insulin, adiponectin
and leptin. In order to avoid possible confounders in
assessing hormone levels at birth, we took blood sam-
ples from the neonates on the 2
nd d a yo fl i f ea n dd i d
not use cord blood in which hormone levels may derive
from the maternal circulation or from other maternal
tissues, such as the placenta [22,23].
The study protocol was approved by the local Ethics
Committee. The study’sp u r p o s ew a sf u l l ye x p l a i n e dt o
each pregnant woman and written informed consent
was obtained before enrolment.
Glucose was measured immediately using a commer-
cial glucometer (One touch Ultra, Lifescan, Johnson
Johnson company). Blood samples were then centrifuged
and serum was frozen at -20°C until the measurements
were performed.
Serum adiponectin and leptin concentrations were
measured by a commercially available ELISA assay (B-
Bridge International, Inc, Sunnyvale CA, USA and R&D
Systems, Minneapolis MN, USA, respectively). The
minimum detectable concentration for adiponectin was
375 pg/ml and the intra- and inter-assay coefficient of
variation ranges were 3.2-7.3% and 4.6-5.8% for a quality
control range of 0.7-2.9 ng/ml, respectively. The mini-
mum detectable concentration for leptin was 15.6 pg/ml
and the intra- and inter-assay coefficient of variation
ranges were 3.2-3.3% and 3.5-5.4% for a quality control
range of 65-600 ng/ml, respectively.
Serum insulin levels were measured by an automatic
chemiluminescent assay ADVIA centaur IRI (Bayer
Diagnostics Europe, Dublin, Ireland). The minimum
concentration detectable by this assay is 0.1 μU/ml. The
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5.0% and 4.2-6.3% for a quality control range of 0.6-4.0
μU/ml, respectively.
Insulin resistance was estimated with fasting insulin
and glucose levels using the homeostasis model assess-
ment insulin resistance index (HOMA-IR), using the fol-
lowing formula: fasting serum insulin (μU/ml) × fasting
plasma glucose (mmol/L)/22.5.
Although the HOMA-IR measure is less accurate than
the euglycemic clamp method used in large epidemiologi-
cal studies, it is a reasonable alternative to the complicated
clamp method that requires continuous intravenous
administration of insulin and glucose for 3 h to calculate
insulin sensitivity [24]. A HOMA-IR value > 3 was chosen
as an indicator of reduced insulin sensitivity [25].
Even if the gold standard techniques for measuring
insulin sensitivity in children are Bergman’sm i n i m a l
model and the hyperinsulinaemic-euglycemic clamp
[26,27], the evaluation of insulin sensitivity starting from
basal insulin levels has been validated in non-diabetic
children as well as in children of one year of age [28-30]
and the use of HOMA-IR has been reported in previous
paediatric studies [31,32].
Samples of 250 μl of pooled serum were gel-filtered
on HyPrep 16/60 Sephacryl-S-200 High Resolution col-
umns equilibrated with 0.05 M NaH2PO4/0.15 M NaCl/
0.02% NaN3 elution buffer. One minute fractions, eluted
with 0.8 ml/min flow rate, were analysed for adiponectin
content with the ELISA assay.
Data were analysed using the statistical analysis soft-
ware package Statistica 7.0 (Stasoft Inc). Descriptive
statistics were calculated and reported as the mean and
standard deviation. Non parametric tests were used for
statistical analysis. The Mann-Whitney U test for
unpaired samples was used to compare anthropometri-
cal and laboratory parameters between SGA and AGA
infants, at each time point of the study. The non-para-
metric Wilcoxon test for paired samples was used to
compare anthropometrical and laboratory parameters at
different times. Correlations were analysed using the
Spearman rank correlation test. A p value < 0.05 was
considered statistically significant.
Results
Auxology
As shown in table 1, symmetrical SGA infants weighted
less and were shorter at birth, at one and 12 months of
life compared to AGA infants. On the contrary, asym-
metrical SGA infants showed a lower BMI only at birth
and at one month compared to AGA infants. Further-
more, head circumferences were smaller in both symme-
trical and asymmetrical SGA infants from birth to six
months of age but they became comparable to those of
AGA infants at one year. Symmetrical SGA infants
were, by definition, significantly shorter (p < 0.05) than
asymmetrical SGA infants at birth and also at 1, 6 and
12 months of age.
Circulating levels of adiponectin
As shown in figure 1A, both AGA and SGA fasting adi-
ponectin levels showed statistically significant changes
over time (p < 0.0005 by Wilcoxon test). In particular,
Table 1 Anthropometrical measurements of AGA, symmetrical and asymmetrical SGA at birth, 1, 6 and 12 months of
life.
AGA Birth 1 month 6 months 12 months
Length (SDS) 0.31 ± 0.78# 0.39 ± 0.87# -0.15 ± 0.90 -0.40 ± 0.95
Weight (SDS) -0.23 ± 0.66# -0.24 ± 1.22 0.26 ± 0.98 0.19 ± 1.05
BMI (SDS) -0.06 ± 0.84§ 0.70 ± 0.86 0.77 ± 1.14 0.38 ± 1.03
Head circumference (SDS) 0.49 ± 0.76# 0.28 ± 1.05# 0.61 ± 1.14# -0.70 ± 0.69
Symmetrical SGA
Length (SDS) -1.82 ± 0.85* -1.21 ± 1.29* -1.47 ± 0.81* -1.85 ± 0.54*
Weight (SDS) -2.45 ± 0.75* -2.52 ± 1.97*# -1.43 ± 1.54*# -1.93 ± 1.62*
BMI (SDS) -1.53 ± 0.60*§ -0.61 ± 1.19* 0.33 ± 1.19 -0.27 ± 1.02*
Head circumference (SDS) -1.01 ± 0.88* -0.75 ± 1.01* -0.47 ± 0.76* -1.25 ± 0.77
Asymmetrical SGA
Length (SDS) -0.29 ± 0.62^ -0.10 ± 0.69^# -0.47 ± 0.57^ -0.70 ± 0.61^
Weight (SDS) -1.84 ± 0.27*#§ -1.25 ± 0.84* -0.19 ± 1.38 -0.73 ± 1.40
BMI (SDS) -1.80 ± 0.49*#§ -0.54 ± 1.09* 0.62 ± 1.71# 0.22 ± 1.54
Head circumference (SDS) -0.86 ± 0.91* -0.65 ± 1.24* -0.65 ± 1.35* -1.31 ± 1.24
* p < 0.05 versus AGA at corresponding time (Mann-Whitney U test)
^ p < 0.05 versus symmetrical SGA at corresponding time (Mann-Whitney U test)
# p < 0.01 versus 12 months with respect to the same group (Wilcoxon test)
§ p < 0.001 versus 1 month with respect to the same group (Wilcoxon test)
Data are shown as mean ± standard deviation.
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of life and then decreased to lower values at one year of
age in all subjects. Adiponectin levels in AGA and SGA
subjects were comparable at all study time points.
In order to investigate whether SGA and AGA sub-
jects show a different distribution of the isomers for adi-
ponectin, we fractioned adiponectin pooled serum
samples into the three major molecular fractions, using
a validated fast protein liquid chromatography assay. As
shown in figure 2, no differences in the fractional adipo-
nectin levels relative to total adiponectin were found
between AGA and SGA groups at different time points.
No statistically significant correlations were found
between adiponectin levels and auxological parameters
at any time point, in any neonate.
No statistically significant difference in adiponectin
levels was shown between symmetrical and asymmetri-
cal SGA infants at birth and during the first year of life
(table 2). A significant increase in adiponectin values
was observed at the first month of age in both groups of
subjects and then a statistically significant decrease up
to one year of life. Only at six months of age did asym-
metric subjects show higher levels of adiponectin than
AGA subjects.
Circulating levels of leptin
As shown in figure 1B, leptin levels significantly changed
over time both in AGA and SGA infants (p < 0.005 by
Wilcoxon test). In fact, leptin levels significantly
increased from birth to the sixth month in all the neo-
nates and at one year there was a trend to return to
birth levels; although at this time, in SGA subjects, lep-
tin levels were significantly higher than at birth. Circu-
lating leptin concentrations at birth were significantly
higher in AGA neonates than in SGA infants. At the
first, 6
th and 12
th month of age, leptin returned to a
comparable level between the two groups, even if at the
latter time point SGA levels were slightly higher than
AGA values, the difference was not significant.
A comparison of leptin levels for asymmetrical and
symmetrical SGA infants, did not reveal any statistically
significant difference at any time during the study (table
2). In both groups, the levels were low at birth and sig-
nificantly increased until six months.
Leptin concentrations at birth were positively corre-
lated with the BMI (r = 0.363, p < 0.05), birth head cir-
cumference (r = 0.434, p < 0.05) and insulin levels (r =
0.448, p < 0.05) in all the infants. After birth, a positive
correlation between leptin levels and BMI at six months
was found (R = 0.406; p < 0.05) in all neonates and also
for AGA and SGA subjects separately.
Circulating levels of insulin
As shown in figure 1C, insulin levels in both AGA and
SGA infants increased over the study period (p < 0.05 by
Wilcoxon test); they were significantly lower (p < 0.05) at
birth compared to the time points one, six and 12
months of age. SGA circulating insulin levels at birth
were lower than AGA levels, although the difference was
not statistically significant. At 1, 6 and 12 months, insulin
concentrations were comparable between the two groups.
Insulin concentrations for symmetrical and asymme-
trical SGA infants were not statistically different at any
study time point (table 2), although in asymmetrical
subjects they tended to be lower than in symmetrical
infants after the first month of age. In both groups,
insulin levels were low at birth and tended to increase
after the first month of life.
Insulin concentrations at one year of age positively
correlated with the BMI (r = 0.408, p < 0.05) and head
circumference (r = 0.436, p < 0.05) in all the infants. No
other correlations were found at the other time points.
Figure 1 Circulating levels of adiponectin, leptin and insulin. Circulating levels of adiponectin (A), leptin (B) and insulin (C) in AGA (white
bars) and SGA (shaded bars) infants at birth and after 1, 6 and 12 months of age. Data are represented as mean+standard deviation. * p < 0.05
AGA versus SGA (Mann-Whitney U test). ^ p < 0.05 AGA or SGA with respect to values at birth (Wilcoxon test). ° p < 0.05 AGA or SGA with
respect to values at 1 month (Wilcoxon test). # p < 0.05 SGA with respect to values at 6 months (Wilcoxon test).
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SGA subjects during the first year of life, we calculated
the HOMA-IR index. Like insulin levels, the HOMA-IR
index was comparable between AGA and SGA infants
at birth and at all study time points (data not shown).
The HOMA-IR index was lower at birth in both groups
(p < 0.01) and then increased from the first month to
12 months of age, remaining in the normal range [25].
The HOMA-IR index was also comparable between
asymmetric and symmetric SGA infants at all time points.
To further verify the relationship between changes in
height SDS and BMI SDS with those of adiponectin, lep-
tin and insulin, we calculated the delta between birth
and the first year of life for each parameter and the rela-
tionship between each parameter pair (data not shown).
We did not observe any significant correlations.
Discussion
This study presents longitudinal data, from birth to one
year of age, on anthropometrical development and
serum adiponectin, leptin and insulin levels in a cohort
of AGA and SGA infants, including both symmetrical
and asymmetrical neonates.
To the best of our knowledge, adiponectin and leptin
studies at birth have always been performed on cord
blood, which is not considered the ideal material for
evaluating these growth stimulating-factors. As we pre-
viously indicated, cord blood may present confounding
factors [22-25,33]. Our study is the first to report actual
circulating levels at birth.
The relationship between adiponectin and foetal
growth has been poorly investigated. Some authors have
found a positive association between cord blood adipo-
nectin levels and birth-weight [33,34], while others have
not [35]. In our study, no significant difference in adipo-
nectin levels was shown between AGA and SGA infants
at birth, although SGA neonates weighed significantly
less than AGA infants. This result is in accordance with
the literature, particularly w i t ht h eK a m o d ae ta l .s t u d y
[36].
Figure 2 Fractional ratios to total adiponectin. Fractional ratios to total adiponectin in AGA (white bars) and SGA (shaded bars) infants at
birth (panel A), after 1 (panel B), 6 (panel C) and 12 months (panel D) of age. T = total adiponectin. H = high molecular weight. M = medium
molecular weight. L = low molecular weight.
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birth weight and the physiological relationship with
adiposity, observed in adults, is absent at birth.
We found that adiponectin levels in both AGA and
SGA neonates were higher than those found in healthy
adults in other studies [35]. This is probably due to a lack
of negative feedback on adiponectin production resulting
from a lack of adipocyte hypertrophy, a low percentage
of body fat or a different distribution of fat depots in
newborns [37]. The analysis of adipose tissue histology in
newborns demonstrated the presence of small cells, that
do not contain fat, and larger cells, that contain fat but
are small in diameter compared with adult fat cells [37].
These cells are responsible for the increased adiponectin
synthesis in neonates. The fall in adiponectin levels at
one year of life may be a consequence of the increase in
adiposity; as in older children, where adiponectin levels
negatively correlate with the percentage of body fat. It
has also been reported that low plasma adiponectin con-
centrations are closely related to hyperinsulinaemia in
children [38,39]. The lower levels of adiponectin in chil-
dren at 12 months of age could therefore also be related
to the increased concentration of insulin at this time. At
one year of age, no statistically significant difference is
present in adiponectin levels between AGA and SGA
infants, indicating that the long-term risk of diabetes,
which has been reported to be associated with low
adiponectin levels in prepubertal children [40], is the
same in the two groups at this time. In fact, a recent
study suggests that the negative correlation between high
molecular weight (HMW) adiponectinaemia and fasting
insulin levels emerges between two and six years of age
and only during this period could a condition of insulin
resistance be evidenced [41].
We have also evaluated adiponectin fractions with dif-
ferent molecular weights in SGA and AGA neonates, in
order to verify if there was a peculiar distribution of adi-
ponectin isomers. We found a similar chromatographic
pattern of adiponectin fractions in AGA and SGA sub-
jects, during the first year of life, confirming the absence
of modifications in total circulating adiponectin.
Furthermore, in other recent studies by Ibanez et al.
[41,42], the authors show comparable levels of HMW
adiponectin in AGA and SGA children at age two; the
HMW adiponectin concentrations decrease and become
significantly lower in SGA children only at age four.
Interestingly, in this study we found leptin levels to be
higher in AGA neonates with respect to SGA infants at
birth, in accordance with recent studies [43]. On the con-
trary, at one year of age SGA infants had leptin levels
higher than AGA subjects, although the difference was not
statistically significant. Small for gestational age infants
show an increase in adipose tissue that is a typical phe-
nomenon after a period of undernutrition. Therefore, we
Table 2 Circulating levels of adiponectin, leptin and insulin in AGA, symmetrical and asymmetrical SGA at birth, 1, 6
and 12 months of life.
AGA Birth 1
month
6
months
12 months
Adiponectin
(μg/ml)
46.7 ± 11.5#* 77.32 ± 24.95# 43.31 ± 20.94 38.56 ± 13.86
Leptin (ng/ml) 2.12 ± 4.08* 3.18 ± 1.64# 2.97 ± 1.76 1.31 ± 0.83
Insulin (μUI/ml) 2.53 ± 1.58*# 7.75 ± 5.61 7.94 ± 7.06 8.66 ± 6.52
SGA
Adiponectin
(μg/ml)
47.74 ± 11.38 75.71 ± 20.75 53.75 ± 18.71 35.51 ± 8.76
Leptin (ng/ml) 0.88 ± 1.04§ 4.49 ± 5.99 4.36 ± 1.69§ 1.74 ± 0.96
Insulin (μUI/ml) 8.92 ± 6.05 8.92 ± 6.05 7.17 ± 6.44 8.13 ± 7.67
Symmetrical SGA
Adiponectin
(μg/ml)
49.03 ± 9.93* 79.78 ± 25.29# 44.42 ± 15.75 33.68 ± 9.17
Leptin (ng/ml) 0.62 ± 0.37* 6.58 ± 8.06 4.67 ± 1.34 2.17 ± 1.29
Insulin (μUI/ml) 2.07 ± 1.97* 8.96 ± 5.55 6.83 ± 3.22 10.0 ± 8.8
Asymmetrical SGA
Adiponectin
(μg/ml)
46.73 ± 12.89* 71.64 ± 15.42# 64.65 ± 16.68§ 36.82 ± 8.93
Leptin (ng/ml) 1.1 ± 1.4 2.4 ± 1.6 4.0 ± 2.1# 1.4 ± 0.56
Insulin (μUI/ml) 3.17 ± 2.67* 8.89 ± 6.77 7.51 ± 8.91 5.43 ± 3.37
§ p < 0.05 versus AGA at corresponding time (Mann-Whitney U test)
# p < 0.01 versus 12 months of the same group (Wilcoxon test)
* p < 0.001 versus 1 month of the same group (Wilcoxon test)
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from this increased adipose tissue and may be involved in
the early development of insulin resistance [28].
Leptin levels of all the neonates at birth were posi-
tively correlated with the BMI and head circumference.
This may reflect either a simple relationship with adi-
pose tissue or an active role for leptin in foetal growth,
since it is known that leptin plays a role in the develop-
ment of both the foetus and neonate, influencing also
head circumference.
In our report we demonstrated comparable insulin
levels and HOMA-IR indices between AGA and SGA
i n f a n t sa tb i r t ha n da t1 ,6a n d1 2m o n t h so fa g e .O n l y
at birth, were levels of insulin in SGA neonates lower
than in AGA infants, but the difference was not statisti-
cally significant, probably due to the relatively low num-
ber of subjects enrolled in the study. However, insulin
levels and HOMA-IR index still remained in the normal
range in SGA subjects during the first year of age, sug-
gesting that no insulin resistance develops during this
period and that insulin alone does not explain changes
in adiponectin levels.
The discrepancies between our results and those
showing different insulin levels at birth between AGA
and SGA infants and a relationship between birth
weight with insulin resistance [43-47] could reflect
methodological differences in the assessment of insulin
sensitivity and insulin resistance.
Conclusions
In conclusion, minor changes in serum adiponectin, lep-
tin and insulin levels can be observed in AGA and SGA
infants during the first year of life. In particular, a pro-
gressive decrease in adiponectin levels is observed, while
leptin values change according to nutritional status. In
fact, leptin levels in all neonates either at birth or at 6
months positively correlated with the BMI (p < 0.05),
confirming that leptin is involved in the regulation of
body weight and that its plasma level reflects fat
reserves.
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